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OBJECTIVES This study sought to evaluate the effects of postmenopausal estrogen use on mortality in aging
women with congestive heart failure (CHF).
BACKGROUND The age-related increase in CHF mortality in women may be related to a menopause-
associated increased incidence of coronary artery disease. In addition to inhibiting coronary
atherosclerosis, estrogen may also have protective effects on cardiac myocytes independent of
the coronary vasculature. We hypothesized that estrogen use is associated with improved
survival in elderly women with CHF.
METHODS Associations between survival, estrogen use and patient characteristics were assessed in 1,134
women who were at least 50 years of age, had CHF and left ventricular ejection fraction (EF)
#30% and were enrolled in one of three clinical trials of vesnarinone.
RESULTS All-cause 12-month mortality was 15.0% among the 237 estrogen users versus 27.1% among
the 897 estrogen nonusers (p 5 0.004 for unadjusted comparison of survival). Similar results
were observed for cardiac mortality. Regression analysis demonstrated that estrogen use was
independently associated with improved survival (relative risk of mortality 5 0.68, 95%
confidence interval 0.48 to 0.96, p 5 0.03). Advanced age, low EF, New York Heart
Association class IV CHF, Caucasian race and abnormal serum creatinine, sodium, potassium
and transaminase were independently associated with increased mortality.
CONCLUSIONS Estrogen use among older women with CHF is associated with decreased overall and cardiac
mortality. (J Am Coll Cardiol 2000;36:529–33) © 2000 by the American College of
Cardiology
Congestive heart failure (CHF) represents the leading
hospital discharge diagnosis for the elderly. Because of
limited inclusion of women, epidemiologic studies and
clinical trials have failed to provide sufficient information
about the outcome of older women with CHF and the
influence of gender-specific cardiovascular physiology on
CHF mortality. Although the age-dependent increased
mortality in CHF patients may be related to an increased
incidence of coronary artery disease (CAD) and ischemic
cardiomyopathy, the effects of menopause-related estrogen
loss on CHF in women are not known. Recent reports of
gender-related differences in cardiovascular physiology pro-
vide speculative evidence that estrogen may have protective
effects on the myocardium (1,2). We hypothesized that
estrogen use among older women with CHF is associated
with improved outcome.
METHODS
The influence of estrogen use on CHF outcome among
aging women was studied using a database of 1,134 women
with symptomatic CHF over the age of 50 years who were
enrolled in the:
1) Multicenter Vesnarinone Study, a randomized, double-
blind, placebo-controlled trial of 60 and 120 mg of
vesnarinone (Otsuka Pharmaceutical Company Ltd.,
Osaka, Japan; n 5 54) (3);
2) Randomized Multiple Dose Study of the Chronic Ad-
ministration of Vesnarinone, a randomized, double-
blind study of 30 and 60 mg of vesnarinone (n 5 323);
or
3) Vesnarinone Trial (VesT), a randomized, double-blind,
placebo-controlled study of 30 and 60 mg of vesnarinone
(n 5 757) (4).
The entry criteria for all studies were similar; subjects were
at least 18 years of age, had symptomatic CHF in spite of
traditional therapy and had a left ventricular ejection frac-
tion (EF) of #30% by radionuclide ventriculography per-
formed within two weeks of randomization. Subjects were
excluded if they were women of childbearing potential;
developed CHF within one year of childbirth; or had a
history of myocardial infarction or cardiac surgery within
the prior three months, severe or unstable angina, a revers-
ible etiology for their myocardial failure, hemodynamically
significant pericardial disease, ventricular fibrillation, im-
plantible defibrillator, significant aortic or mitral stenosis or
a life-limiting comorbidity or lupus. Additional exclusion
criteria included concomitant therapy with ticlopidine, clo-
zapine, encainide, flecainide, tocainide, use of intravenous
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inotropes at the time of screening or a history of agranulo-
cytosis or drug-induced neutropenia.
Estrogen users were taking oral or transdermal estrogen
at study entry alone or in combination with a progestin.
Differences in distributions of continuous and ordered
categorical variables between estrogen users and nonusers
were assessed using the Kruskal-Wallis test; distributions of
two-level and unordered categorical variables were com-
pared using the Fisher exact test.
Median follow-up was 309 days. Rates of all-cause and
cardiac mortality (i.e., sudden death, CHF or myocardial
infarction) were calculated using the Kaplan-Meier method,
with transplanted patients censored at the time of trans-
plantation. For the 54 women in the Multicenter Vesnari-
none Study, the three deaths were not classified by cardiac
versus noncardiac, and, thus, this entire cohort was excluded
from the cardiac mortality analyses. The log-rank test was
used to compare unadjusted survival curves between estro-
gen user and nonuser groups.
The primary study outcome was the relative risk of
mortality for estrogen users versus nonusers, adjusted for the
effects of the study drug and other factors. To assess the
associations of patient characteristics with mortality, univar-
iate and multivariate Cox proportional hazards regression
was used. Although drug dosage, specific trial, and all
available clinical factors were used in the reported multivar-
iate model (regardless of statistical significance), backwards
elimination of nonsignificant terms did not affect the
magnitude or significance of the estrogen use indicator.
RESULTS
Clinical characteristics. Of the 1,134 women, 897 were
estrogen nonusers, and 237 were estrogen users. Table 1
shows that estrogen nonusers were four years older than
users and more likely to be non-Caucasian. The statistically
significant differences observed between groups in EF,
creatinine, potassium, sodium and aspartate aminotransfer-
ase (AST) were of a small magnitude.
Influence of estrogen on mortality. Figure 1 presents
Kaplan-Meier survival curves by estrogen use. Unadjusted
12-month all-cause mortality rates for estrogen nonusers
and users were 27.1% and 15.0%, respectively (p 5 0.004).
Similar analysis demonstrated that 12-month cardiac mor-
tality (sudden death, CHF or myocardial infarction) was
25.6% and 14.0% for estrogen nonusers and users, respec-
tively (p 5 0.007). These findings were consistent within
each of the vesnarinone studies. Analyses stratified for type
of estrogen therapy demonstrated that the 186 unopposed
Abbreviations and Acronyms
AST 5 serum aspartate aminotransferase
CAD 5 coronary artery disease
CHF 5 congestive heart failure
EF 5 ejection fraction
HERS 5 Heart and Estrogen/progestin Replacement
Study
NYHA 5 New York Heart Association
RR 5 relative risk
Table 1. Baseline Characteristics of Women According to Estrogen Use
Estrogen Nonusers
(n 5 897)
Estrogen Users
(n 5 237) p Value
Age (years) 66.5 6 8.9 62.4 6 8.2 , 0.001
Race (%) , 0.001
Caucasian 79.3 92.8
African-American 16.4 6.8
Other 4.3 0.4
Ejection fraction (%) 20.8 6 6.0 22.1 6 5.6 0.004
NYHA (%) NS
I 0.2 0.0
II 5.9 7.2
III 76.5 78.5
IV 17.4 14.3
Creatinine (mmol/L) 1.33 6 0.40 1.26 6 0.36 0.002
Sodium (mmol/L) 138.9 6 3.8 138.3 6 3.4 0.013
Potassium (mmol/L) 4.38 6 0.54 4.29 6 0.44 0.020
AST (U/L) 23.5 6 15.6 23.4 6 19.8 0.007
Vesnarinone (%) NS
Placebo 24.0 26.6
30 mg 38.4 33.8
60 mg 36.6 39.7
120 mg 1.1 0.0
Etiology (%) 0.065
Ischemic 47.6 39.7
Nonischemic 51.1 58.2
Unknown 1.3 2.1
Continuous data are expressed as means 6 standard deviations. Categorical data are expressed as percentage of patients.
AST 5 serum aspartate aminotransferase; NYHA 5 New York Heart Association.
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estrogen users had a significant survival benefit compared
with the 897 hormone nonusers (relative risk [RR] for
death 5 0.57, p 5 0.004). Survival for the 51 combined
estrogen and progestin users was intermediate between that
of unopposed estrogen users and hormone nonusers. How-
ever, we found no statistically significant difference in
12-month survival between women using unopposed estro-
gen and those using combination estrogen and progestin
therapy (RR 5 0.75, p 5 0.42; Fig. 2). There was also no
statistically significant difference in survival between com-
bination estrogen plus progestin users and hormone nonus-
ers (RR 5 0.77, p 5 0.41). Table 2 shows all deaths
reported during follow-up (median 323 days) for the 1,080
women participating in trials in which cause of death was
identified. These data demonstrate that, regardless of hor-
mone use or hormone type, almost all deaths were classified
as cardiac deaths, the majority of which were either sudden
death or attributable to worsening CHF.
Univariate Cox regression analysis demonstrated that
estrogen users had a significantly lower all-cause mortality
than nonusers (Table 3; RR for users vs. nonusers: 0.61, p 5
0.004). Other univariate predictors of death were age, EF,
creatinine, potassium, sodium, AST, Caucasian race and
New York Heart Association (NYHA) class IV CHF.
There was a trend for increased mortality among women
assigned to vesnarinone compared with placebo. After
adjustment for these factors, estrogen use remained inde-
pendently associated with lower mortality (adjusted RR:
0.68, p 5 0.03). No evidence of an interaction between
vesnarinone dose and estrogen use was found in the mor-
tality analysis.
Mortality effects of estrogen in ischemic cardiomyopathy.
Because estrogen has antiatherosclerotic properties, sub-
group analysis was performed to evaluate its effects in
women with and without CAD. Among the 521 women
with clinically defined ischemic cardiomyopathy (i.e., ab-
normal coronary angiography or stress test or past myocar-
dial infarction), there was a trend toward lower 12-month
mortality in estrogen users (18.6%) versus nonusers (29.7%).
A similar trend was seen among 596 women with idiopathic
(i.e., nonischemic) cardiomyopathy (12-month mortality:
12.8% vs. 24.5%, estrogen users vs. nonusers). Therefore,
estrogen use appears to be associated with lower mortality
regardless of the etiology of cardiomyopathy.
DISCUSSION
Previous studies demonstrate that CHF is associated with
higher mortality among the aging (5). In women, this has
been attributed to an age-related increased incidence of
ischemic cardiomyopathy. However, the clinical and phys-
Figure 1. Kaplan-Meier curves for all-cause mortality according to estro-
gen use (p 5 0.004). Solid line 5 estrogen nonusers; broken line 5
estrogen users.
Figure 2. Kaplan-Meier curves for all-cause mortality for estrogen users
according to type of hormone (p 5 0.42). Solid line 5 estrogen alone;
broken line 5 estrogen/progestin.
Table 2. Classification of All Deaths Occurring During Study
Follow-up, According to Hormone Use*
Unopposed
Estrogen
Estrogen 1
Progestin
No
Hormones
N 181 45 854
Overall deaths 30 10 230
Noncardiac deaths 2 1 17
Cardiac deaths 28 9 213
Sudden death 16 8 106
Worsening CHF 11 1 103
Myocardial
infarction
1 0 4
* The 54 women participating in the Multicenter Vesnarinone Study, of whom three
died, did not have cardiac versus noncardiac mortality classified and are excluded from
this table.
CHF 5 congestive heart failure.
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iologic effects of the absence of estrogen in older women
with CHF have not been described. Our results suggest
that, among aging women, estrogen users have an age-
independent lower mortality than nonusers unrelated to the
etiology of their cardiomyopathy.
Possible physiologic mechanisms for estrogen’s protec-
tive effects. Several mechanisms could account for benefi-
cial effects of estrogen in CHF. First, estrogen has in vivo
vasodilator properties (6,7). Because abnormal peripheral
artery vasoconstriction is found in CHF patients and some
vasodilators decrease CHF mortality, afterload reduction
may provide a mechanism for the observation that post-
menopausal estrogen use is associated with improved CHF
outcome. An alternative hypothesis comes from reports that
estrogen deficiency-induced osteoporosis is mediated by
TNF alpha and that the menopause-associated increase in
monocyte production of proinflammatory cytokines could
be abrogated by estrogen (8,9). Proinflammatory cytokines
are re-expressed by failing cardiac myocytes, elevated in
plasma of CHF patients and are associated with increased
CHF severity (10–12). Thus, estrogen-induced inhibition
of cytokines is another potential mechanism for the ob-
served association between postmenopausal estrogen use
and lower mortality in women with CHF.
Another explanation is that estrogen may have decreased
the incidence of fatal myocardial infarction by virtue of its
atheroprotective effects. Although this is plausible in those
with pre-existing CAD, it is an unlikely explanation in
women without CAD. Our data show a trend toward
improved short-term survival among estrogen users with an
idiopathic (i.e., nonischemic) cardiomyopathy. Therefore,
the observation that estrogen use is associated with lower
mortality in older women with CHF may be independent of
atherosclerosis. Interestingly, our data also show a trend
towards estrogen-associated decreased mortality among
women with ischemic cardiomyopathy. This finding appears
to be contrary to the only reported large-scale prospective
randomized, placebo-controlled trial of postmenopausal
hormones, the Heart and Estrogen/progestin Replacement
Study (HERS), which reported a trend towards a hormone-
associated increased 12-month cardiac mortality in post-
menopausal women with pre-existing CAD. However, few
(9.5%) women in HERS had CHF before randomization,
and a similar small percentage (8.7%) of HERS women
were hospitalized for CHF during long-term follow-up
(i.e., mean 4.1 years) (13). These demographics differ from
this study, in which all subjects had significant symptomatic
heart failure and less than half had CAD. Therefore, the
discrepancy in the effects of hormone use between HERS
and this study may be related to differences in patient
population and not necessarily due to differences in study
design. Another explanation for the discrepancy between
studies is that the majority of hormone users in this study
used unopposed estrogen, while HERS randomized women
to a combined estrogen and progestin. Indeed, our results
suggest a nonsignificant trend toward a progestin-associated
attenuation of estrogen’s beneficial mortality effect in CHF.
This is consistent with previously proposed explanations of
the negative HERS findings; that is, progestin therapy
might mitigate the cardioprotective effects of estrogen (14).
Study limitations. Our exploratory post hoc analysis
pooled data from three clinical trials to obtain a sufficient
population to test our hypothesis. Although this may be
perceived as a limitation, the trials had similar entry criteria
and comparable subject demographics with respect to clin-
ically important factors, and multivariable modeling con-
trolled for covariables, including a separate “study effect.”
Table 3. Patient Characteristics Showing Univariate and Multivariate Associations With All-
cause Mortality by Cox Regression
Univariate Multivariate§
Relative Risk 95% CI Relative Risk 95% CI
Estrogen user (vs. estrogen nonuser) 0.61‡ (0.44, 0.86) 0.68† (0.48, 0.96)
Caucasian (vs. non-Caucasian) 1.64‡ (1.14, 2.36) 1.67‡ (1.14, 2.46)
NYHA IV (vs. I, II or III) 2.47‡ (1.90, 3.20) 2.00‡ (1.53, 2.62)
Vesnarinone (vs. placebo)
30 mg 1.37* (0.97, 1.94) 1.15 (0.79, 1.66)
60 mg 1.39* (0.98, 1.96) 1.32 (0.91, 1.92)
120 mg 1.62 (0.22, 11.82) 4.67 (0.42, 52.4)
Age (per year increase) 1.03‡ (1.02, 1.04) 1.02‡ (1.01, 1.04)
Ejection fraction (per 1% decrease) 1.03‡ (1.01, 1.05) 1.03‡ (1.01, 1.05)
Creatinine (per 1 mmol/L increase) 2.05‡ (1.65, 2.54) 2.02‡ (1.56, 2.63)
Sodium (per 1 mmol/L decrease) 1.12‡ (1.09, 1.16) 1.10‡ (1.07, 1.13)
Potassium (per 1 mmol/L decrease) 1.26* (0.99, 1.61) 1.47‡ (1.17, 1.84)
AST (per 10 U/L increase) 1.06‡ (1.02, 1.10) 1.09‡ (1.04, 1.14)
Etiology (vs. ischemic)
Nonischemic 0.71‡ (0.56, 0.91) 0.91 (0.71, 1.17)
Unknown 0.75 (0.28, 2.03) 1.01 (0.37, 2.77)
* p , 0.10; † p , 0.05; ‡ p , 0.01 for significance of (Wald) test that relative risk is different from 1; § multivariate model
included factors listed above plus a separate effect for the specific vesnarinone trials, which was not statistically significant.
AST 5 serum aspartate aminotransferase; CI 5 confidence interval; NYHA 5 New York Heart Association.
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Another limitation was that the majority of women were
receiving vesnarinone. However, after controlling for
vesnarinone use and dosage, we found that estrogen use
remained independently associated with improved survival.
Finally, we could not control for the possibility that hor-
mone users may have healthier lifestyles than nonusers (15),
because socioeconomic status and other lifestyle measures
were unavailable in the database. However, we hypothesize
that any potential “lifestyle” bias between estrogen users and
nonusers in our study is likely to be relatively small in
magnitude because all subjects volunteered to participate in
a randomized clinical trial of vesnarinone. Previous studies
have demonstrated that subjects voluntarily participating in
clinical trials tend to be highly conscious of their health.
This awareness, together with the close monitoring that
these patients receive while participating in a clinical trial,
may lead to improved outcome among trial participants
regardless of treatment assignment. In addition, estrogen
use remained significantly associated with improved survival
after we controlled for disease severity (NYHA class), which
is likely to be a stronger predictor of CHF survival than is
lifestyle. Nevertheless, the potential “lifestyle” bias suggests
caution in the extrapolation of our findings to more general
populations that may substantially differ from our study
patients in terms of overall health or other important
factors.
Conclusions. These results suggest that in older women
with CHF, estrogen use is associated with lower overall and
cardiac mortality that is independent of age, vesnarinone
use, EF and CHF severity. This observation from a retro-
spective analysis of a large database of women with CHF
generates a new hypothesis that needs to be tested by
prospective large-scale randomized clinical trials.
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